Cidara's CD388: FDA Meeting Boosts Outlook

FDA fast-tracked Cidara's CD388 flu drug trial by 6 months. Only one successful trial is needed for approval. Including seniors (65+) means a bigger market (5M+ patients) & higher analyst price targets ($137), boosting the stock by 16%.